Rizvi Syed Ali-aamir 4

What Happened
Rizvi Syed Ali-aamir, Chief Medical Officer of Rocket Pharmaceuticals (RCKT), received equity awards on February 11, 2026: 61,963 restricted stock units (RSUs) and a derivative grant representing a right to purchase 93,037 shares. Both awards are shown at $0.00 purchase price in the Form 4 (i.e., a grant/award, not a market purchase), so no cash was paid at grant.

Key Details

• Transaction date: February 11, 2026; Form 4 filed February 13, 2026 (appears timely under the two-business-day filing rule).
• RSUs: 61,963 shares granted at $0.00 (Footnote F1/F2).
• Option/derivative: Right to purchase 93,037 shares shown as acquired at $0.00 (Footnote F3).
• Vesting: One-third of each award vests on February 11, 2027; the remaining two-thirds vest in equal quarterly installments over the subsequent two years, subject to continued employment (F2/F3).
• Shares owned after transaction: not disclosed in the provided excerpt of the filing.
• Transaction code: A = Award/Grant; the second line is a derivative (option) rather than an immediate stock purchase or sale.

Context
RSUs convert to common stock on a one-for-one basis when they vest (per F1). The option grant is a standard time‑based vesting award (not an immediate exercise or cashless sale); exercising the option in the future would require payment of the exercise price and may trigger a separate Form 4 when exercised or when shares are sold. These awards are routine compensation for executives and do not by themselves signal a buy or sell in the open market.